clinical trial · NCT06847542
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Hoffmann-La Roche·phase3·recruiting·n = 250
Neovascular Age-related Macular DegenerationSusvimo PDS ImplantRanibizumab
brief summary
The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.
started
Nov 27, 2025
primary completion
Sep 12, 2028
completion
Oct 12, 2028
last updated
Mar 30, 2026
official title
A Phase IIIb, Multicenter, Single-arm Study Assessing the Effectiveness, Safety and Patient Reported Outcomes of a 36-week Refill Exchange Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol